Molbio Diagnostics Limited

Total Issue Size

₹939.7 Cr

1,16,46,246 shares

Fresh Issue

₹200.12 Cr

24,80,246 shares

Offer for Sale

₹739.57 Cr

91,66,000 shares

Face Value

₹1 per share

Issue Type

Book-built IPO

Listing At

BSE, NSE

Shares Pre-Issue

11,27,59,750

Shares Post-Issue

11,52,39,996

1. Offer opens

   10 Aug 2026

2. Offer closes

   12 Aug 2026

3. Allotment

   13 Aug 2026

4. Listing

   17 Aug 2026

• Anchor29.9%34,87,717 shares
• QIB20.0%23,25,145 shares
• HNI15.0%17,43,860 shares
• Retail34.9%40,69,005 shares
• Employee0.2%20,519 shares

Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities. The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics. As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions. Strengths Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology. Strong R&D capabilities supported by an extensive global patent portfolio. Scalable business model with recurring revenues from diagnostic test kits. Global presence across 90+ countries with strong government and institutional customer base. Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio. Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.

• Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. (₹105.54 Cr)
• Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and (₹72.28 Cr)
• General Corporate Purposes (₹9.47 Cr)
• Issue Expenses (₹59.54 Cr)

• <p>Sriram Natarajan
• Chandrasekhar Bhaskaran Nair
• Sangeetha Sriram
• Shiva Sriram
• Sowmya Sriram
• Exxora Trading LLP</p>

Book running lead managers

• Kotak Mahindra Capital Co.Ltd.
• IIFL Capital Services Ltd.
• Jefferies India Pvt.Ltd.
• Motilal Oswal Investment Advisors Ltd.

Registered office

Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722

• DRHPDraft Red Herring Prospectus
• RHPRed Herring Prospectus
• AnchorAnchor Investor List